The person who commissioned Deer was Paul Nuki, Sunday Times' sometime Head of Newsroom investigations and "Focus" editor. Paul Nuki is son of Professor George Nuki. Professor George Nuki in 1987 sat on the Committee on Safety of Medicines when the CSM was considering Glaxo company Smith Kline & French Laboratories' Pluserix MMR vaccine for safety approval. ......sitting on the CSM with Professor George Nuki was Professor Sir Roy Meadow and Professor Sir David Hull............it was Professor Sir David Hull in 1998 who, as chairman of the Joint Committee on Vaccination and Immunisation, started the attacks on Wakefield's work 
    As Chairman of the JCVI, Professor Sir David Hull could have taken action to deal with the issues over the MMR and protect British children
    In 1998 Professor Sir David Hull wrote (on home headed notepaper) to Dean Zuckerman of The Royal Free, suggesting the Royal Free Hospital's work was unethical research without clinical justification (wrongfully, as the public would have learnt if The Observer had been reporting the current GMC hearings into the Wakefield case)
    Despite his attacks on Wakefield's work, two years later in 2000, it was Professor Sir David Hull who rewrote the Royal College of Paediatrics and Child Health ethical guidelines to permit research on children where there was no clinical benefit (albeit in The Royal Free's case all the investigations were clinically justified)  [April 2008] MMR/AUTISM & THE TAMING OF THE BRITISH MEDIA--Clifford Miller

"Four of the medical experts advising the Government on whether the new meningitis C vaccine is safe have links to one or more of the drug companies that produce it......Professor Janet Darbyshire, a member of the Government's Committee on Safety of Medicines, had received support for academic research from US firms Wyeth and Chiron, who produce the two main meningitis products being used on children in Britain....three members of the Joint Committee on Vaccination and Immunisation had declared interests in vaccine manufacturers...Dr David Goldblatt of the Institute of Child Health, has served on an expert advisory panel for Wyeth and received research grants from Wyeth and North American Vaccines, which produces a third meningitis C drug to be introduced this year. Another, Professor Keith Cartwright of the University of Bristol, received funding from the drug industry to 'evaluate candidate meningicoccal vaccines'. "--Martin Bright and Tracy McVeigh,  Sunday Observer, UK September 3, 2000

"A Parliamentary Written Question by Mrs. Ann Winterton MP in May 1999 confirmed the following declared interests within the JCVI membership (NB - the PWQ related only to a limited range of pharmaceuticals companies, so the full list will be greater than this): Professor Lewis Ritchie (Glaxo Wellcome), Dr. Barbara Bannister (Glaxo Wellcome and SmithKline Beecham),  Dr. David Goldblatt (SmithKline Beecham), Dr. Diana Walford (Glaxo Wellcome and SmithKline Beecham), Professor Roy Anderson (Glaxo Wellcome and SmithKline Beecham), Dr. Karl Nicholson (Glaxo Wellcome)"--David Thrower Flawed UK Regulatory and Monitoring Systems (2001)

 The Chairman reminded  members that the proceedings,  papers, and information before them were confidential and should not be disclosed

Parliamentary Ombudsman Investigations Completed July 2003 - June 2004 Department of Health Refusal to provide information about the awarding of a contract to supply a stock of smallpox vaccine
Ms Branigan originally asked DoH for a number of pieces of information relating to the awarding of a contract to PowderJect Technologies PLC to supply a stock of smallpox vaccine. She then asked 17 Government Departments, including DoH, for information relating to contacts between their respective Ministers and representatives of PowderJect. Finally, she asked DoH for several pieces of information relating to the work of the sub- group of the Joint Committee on Vaccination and Immunisation, which had given advice on the choice of the particular smallpox vaccine strain. DoH declined to release most of the information sought by Ms Branigan and cited a number of code exemptions in justification. After a protracted investigation, beset by DoH delays, the Ombudsman recommended that almost all the information sought by Ms Branigan be released. Following a further exchange of correspondence, DoH agreed to the release of information which had already entered the public domain but either refused to address the remaining recommendations or refused to release the information recommended for disclosure. The Ombudsman criticised the manner in which DoH had handled Ms Branigan's information requests and for their failure to engage effectively with her own investigation.
.......In respect of the letter of 29 May 2002, DoH: have continued to refuse to confirm the identities of the second and third members of the JCVI sub-group even though the identity of the second member is already in the public domain ; have refused to release the names of the organisations to whom the other members of the sub-group belonged, and have apparently refused to release the information contained in the document headed 'Main Points', which summarises that meeting.